其他

港股IPO招股书披露先例 · 10 家公司,10 项

合规类事项自 2026 年 8 月 24 日起递交的文件开始收录。

2026-09-28PHIP不合规事项
安徽希磁科技股份有限公司Anhui Sinomags Technology Co., Ltd

25项专利被提起无效宣告请求

During the Track Record Period, the Petitioner had filed patent invalidation proceedings against 25 patents (the "Disputed Patents").

Business · 第 182 页

However, following examination of materials submitted by the Petitioner, the Patent Re-examination Department declared 20 patents invalid and two patents partially invalid primarily on the basis of lack of inventiveness.

Business · 第 183 页

for two of such patents, the Patent Re-examination Department’s decision declaring the patents invalid was upheld by the Beijing Intellectual Property Court at first instance, following which we filed appeals to the Supreme People’s Court, and such appeals remained pending as of the Latest Practicable Date

Business · 第 183 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-28Prospectus合规确认
北京奕斯伟计算技术股份有限公司Beijing ESWIN Computing Technology Co., Ltd.01256.HK

部分项目开源许可义务之适用分析

Approximately 10.6% of these projects were subject to obligations arising from the relevant open-source software licenses, which require that if we modify certain software components, the modified source code must also be open sourced.

Business · 第 160 页

Accordingly, such partial software open-source obligations will not result in negative impact on our research and development, production, or business operations, nor will they lead to the leakage of our technological secrets or impairment of our intellectual property rights.

Business · 第 160 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-14Prospectus合规确认
深圳四方精创资讯股份有限公司Shenzhen Forms Syntron Information Co., Ltd.06700.HK

开源软件使用符合许可条款

During the Track Record Period and up to the Latest Practicable Date, we confirm that we have utilized open-source software in the PRC in compliance with the relevant license terms as follows: (a) our use is limited to compression, development, database and debugging tools as auxiliary development tools, without any modification, resale, lease or secondary distribution

Business · 第 153 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-11Application Proof合规确认
翱捷科技股份有限公司ASR MICROELECTRONICS CO., LTD.

知识产权法律法规合规之确认

As advised by our PRC Legal Advisor, during the Track Record Period and up to the Latest Practicable Date, we had complied with all PRC applicable intellectual property laws and regulations in all material respects.

Business · 第 156 页

As of June 30, 2026, we had 246 registered patents, 46 trademarks, 21 software copyrights, 161 integrated circuit layout design rights and one domain name registered in the PRC.

Business · 第 156 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-31Prospectus合规确认
优地机器人(无锡)股份有限公司Excelland Robotics (Wuxi) Co. Ltd.03231.HK

对视觉感知算法的使用无重大法律障碍

As advised by our PRC Legal Adviser, under the relevant agreements and statement, although our rights are non-exclusive, we have rights to use the Vision Perception Algorithm, source code and SDK software.

Business · 第 175 页

As further advised by our PRC Legal Adviser, there is no material legal impediment to our Group's use of the Vision Perception Algorithm and the related source code.

Business · 第 175 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof合规确认

自由实施分析未发现侵犯第三方专利

Based on the FTO Analysis, our Directors are of the view that there are no valid and enforceable patents of any third party in China and the U.S. covering the amino acid sequences or indications currently under development of our Core Products and we have not infringed any valid and enforceable patents or other IP rights of any third parties.

Business · 第 212 页

No valid claims of third party patents in the U.S. and the PRC that are infringed by FT-002 or FT-003 have been identified.

Business · 第 211 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof合规确认
维眸生物科技(浙江)股份有限公司VivaVision Biotech (Zhejiang) Co., Ltd.

核心产品FTO分析及不侵权确认

We have engaged our PRC IP Counsel and U.S. IP Counsel to carry out freedom-to-operate (FTO) analyses with respect to our Core Products.

Business · 第 212 页

Based on the FTO analyses, we were not aware of any issued patents that may affect our rights to conduct research and development or commercialization of our Core Products in China and the United States as of the Latest Practicable Date.

Business · 第 212 页

Directors are of the view that we have maintained sufficient intellectual property protection for our Core Products and product candidates, as well as their associated technologies, and had not infringed any third-party intellectual property rights during the Track Record Period and up to the Latest Practicable Date.

Business · 第 213 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof合规确认
南京诺令生物科技股份有限公司Nanjing Novlead Biotechnology Co., Ltd.

自由实施(FTO)分析及知识产权合规确认

Based on the freedom-to-operate (“FTO”) analysis, as of August 18, 2026, there is no substantial risk of infringement of valid and enforceable issued patents of any third party in the Chinese mainland, Europe and the U.S. that may impact the development and commercialization of our Core Product in the Chinese mainland, Europe and the U.S.

Business · 第 191 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us